July 11, 2012 6:33 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that the United Kingdom High Court of Justice issued a decision in favor of Teva in a patent litigation proceeding against Generics (UK) Limited, a subsidiary of Mylan Laboratories Inc., on July 11, 2012. Generics (UK) Limited commenced the proceeding in the UK to seek the revocation of European Patent (UK) 762,888, a patent for COPAXONE® (glatiramer acetate injection) expiring May 23, 2015, and to obtain a declaration that its proposed generic version of COPAXONE® would not infringe the ‘888 patent. The High Court specifically determined that the asserted claims of the ‘888 patent were valid, and also declined to issue a declaration that Generics UK's proposed generic version of COPAXONE® would not infringe the ‘888 patent.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.